Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 16/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24452410 | 0.93 | NR1H4 (0.38) | NR1H4FFAR4FFAR1NR1I2CYP2C9 | |
| SCHEMBL24452395 | 0.89 | NR1H4 (0.47) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24452477 | 0.85 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL22352733 | 0.84 | NR1H4 (0.36) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22348271 | 0.82 | NR1H4 (0.54) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22352868 | 0.79 | NR1H4 (0.40) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24452472 | 0.77 | NR1H4 (0.42) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22352999 | 0.77 | MAPT (0.41) | NR1H4FFAR4FFAR1NR1I2CYP2C9 | |
| SCHEMBL22348297 | 0.77 | NR1H4 (0.56) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24452240 | 0.76 | NR1H4 (0.58) | NR1H4NR1I2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885FFAR4 54/4885FFAR1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.